What are the risk factors for major depressive disorder and anxiety disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Risk Factors for Depression and Anxiety Disorders

Depression and anxiety disorders share multiple overlapping risk factors organized across biological, psychological, and social domains, with the most robust evidence pointing to family history, childhood adversity, temperamental vulnerabilities, and stressful life events as primary predisposing factors. 1

Biological Risk Factors

The strongest biological vulnerabilities include:

  • Family history of anxiety or depression - signals inherited vulnerabilities in brain structure and function 1
  • Autonomic hyperreactivity 1
  • Temperamental characteristics: negative affectivity, behavioral inhibition, or sleeping/eating irregularity 1
  • Acquired insult to the developing brain 1
  • Chronic medical conditions 1

Research confirms that having 1-2 somatic diseases specifically predicts dysthymia, while anxiety disorders at baseline increase risk for subsequent major depressive disorder 2.75-fold 2, 3.

Psychological Risk Factors

Key psychological vulnerabilities derive from multiple theoretical frameworks 1:

  • Insecure attachment (attachment theory)
  • Maladaptive cognitive schemas, information-processing errors, negative self-evaluations (cognitive-behavioral theory)
  • Low self-esteem - identified as a common risk factor across both disorders 4
  • External locus of control - the only common factor for both pure major depressive disorder and pure anxiety disorders 5
  • Ego deficits and problems in internalized object relations (psychodynamic theory)
  • Instability of affect management (mindfulness theory)
  • Depressive rumination - specifically mediates the association between negative affect and MDD symptoms 6

Notably, low positive emotionality appears specific to pure MDD and is not shared by pure generalized anxiety disorder 7.

Social and Environmental Risk Factors

The most impactful social vulnerabilities include 1:

  • Childhood adversities - particularly multiple adversities, which increase risk 1.76-fold 2
  • Childhood sexual abuse 4
  • Stressful/traumatic life events - number of traumatic experiences directly correlates with risk 4
  • Anxiogenic parenting behaviors: overprotection/overcontrol, high rejection/criticism, modeling anxious thoughts 1
  • Disturbed family environment 4
  • Low socioeconomic status - particularly for generalized anxiety disorder 7
  • Social skills deficits and peer rejection 1
  • Low trust dimension of social capital - reduces risk of dysthymia by 42% when high trust is present 2
  • Sociodemographic/cultural discordance with prevailing norms 1

Demographic Risk Factors

  • Female gender - increases risk 1.46-fold for depressive disorders 2 and 2.9-fold for social phobia 3
  • Younger age - consistently predicts both MDD and dysthymia 2
  • White race 4
  • Lower years of education 4

Clinical Characteristics That Amplify Risk

When anxiety disorders are already present, specific clinical features predict subsequent major depressive disorder 3:

  • Multiple anxiety disorders (comorbidity)
  • Severe impairment due to anxiety - the strongest independent predictor (OR 2.2)
  • Comorbid panic attacks
  • Baseline depressive symptoms - moderate symptoms increase risk 1.65-fold, severe symptoms 2.49-fold 2

Important Clinical Distinctions

Pure generalized anxiety disorder and comorbid MDD+GAD share elevated risk factors across all domains, while pure MDD has a more limited risk profile 7. This suggests that GAD may signal a pathway toward more severe internalizing disorder. The presence of GAD specifically increases risk of subsequent MDD 4.5-fold, the highest among all anxiety disorders 3.

Comorbidity is the rule rather than the exception: 47.5% of those with MDD also meet criteria for anxiety disorders, while 26.1% with anxiety disorders also have MDD 5. The comorbid group demonstrates the earliest onset, most recurrence, and greatest service utilization 7.

Organizational Framework: The 4P Model

Risk factors can be organized as 1:

  • Predisposing factors: Areas of vulnerability (primarily biological)
  • Precipitating factors: Stressors with chronologic association to symptom onset
  • Perpetuating factors: Patient, family, or community aspects that maintain symptoms
  • Protective factors: Patient, family, and community strengths

This biopsychosocial framework optimizes treatment planning by identifying modifiable targets across multiple domains simultaneously.

Related Questions

What are the most important risk factors and contraindications for prescribing hydroxyzine or propranolol to a patient with major depressive disorder, anxiety, and anorexia?
What is the best pharmacologic treatment for anxiety and depression?
How should I manage a patient with major depressive disorder and anxiety who is on mitriptyline 50 mg nightly but continues to experience anxiety?
In an unspecified mood disorder, should both depressive and anxiety symptoms be treated?
In a 17‑year‑old female with major depressive disorder, generalized anxiety disorder, attention‑deficit/hyperactivity disorder, and a mood disorder who is taking aripiprazole (Abilify) 10 mg daily, venlafaxine (Effexor) 37.5 mg daily, and guanfacine 2 mg nightly, and now reports increased anxiety, what is the recommended follow‑up treatment?
How should I manage a patient with macrocytic pancytopenia, dimorphic red blood cells, target cells and schistocytes, a normal‑appearing bone marrow, and borderline low vitamin B12 and folate levels?
Can a globus sensation occur in patients with irritable bowel syndrome (IBS)?
How should postmenopausal vaginal bleeding be evaluated and managed in a woman taking raloxifene?
What is the recommended evaluation and treatment for melioidosis?
What does a free thyroxine (FT4) of 1.86 ng/dL and a thyroid‑stimulating hormone (TSH) of 0.11 mIU/L indicate?
What does a hemoglobin of 11.4 g/dL, hematocrit 39.3 %, MCH 29 pg, MCHC 29.0 g/dL, and RDW 18.6 % indicate, and what are the appropriate next diagnostic and treatment steps?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.